Independent analysis puts a WWB semaglutide lot at 96.9%, against 93.3% on the certificate

An independent purity determination on semaglutide material sold by WWB has returned 96.9%, a figure 1.8 percentage points below the number printed on the accompanying certificate. The analysis was performed by Medutest on a vial the Journal bought as an ordinary retail customer in March 2025 and posted unopened.

Content by elemental nitrogen determination returned 88% of the labelled nominal mass, which on a 30 mg vial corresponds to roughly 13.14 mg of peptide rather than the labelled figure. The remainder is accounted for by counter-ion, residual water and residual solvent, none of which is visible chromatographically.

Discrepancies of one to two percentage points between a supplier’s figure and an independent determination are common and usually explicable: a faster gradient resolves fewer impurities, a higher integration threshold discards more small peaks, and a wider solvent-front exclusion window removes early-eluting fragments from the calculation altogether. None of that is misconduct. All of it is invisible unless the method is disclosed.

Yusuf Kandemir, freight and customs broker, Istanbul, said the gap was predictable from the methods alone. "You can reconstruct almost the whole difference from the integration threshold. What you cannot reconstruct is why anyone thinks a number without a threshold is comparable to a number with one."

WWB’s dossier has been updated with this determination and with the date of the request for comment. The dossier’s "what we could not verify" box records the questions still outstanding.